We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMN Expands Language Services Portfolio With Jaide Health Deal
Read MoreHide Full Article
Key Takeaways
AMN acquired Jaide Health to expand language access for patients with Limited English Proficiency.
AMN adds AI-assisted translation for intake, discharge and routine interactions, plus documents.
Jaide's team joins AMN; terms weren't disclosed, and human interpreters stay key for complex talks.
AMN Healthcare Services (AMN - Free Report) recently announced the acquisition of Jaide Health, an AI-enabled medical interpretation and translation platform, to expand language access for patients with Limited English Proficiency across the healthcare journey. The move enhances AMN’s Language Services capabilities by extending language assistance to important touchpoints before and after treatment while maintaining the critical role of qualified human interpreters for clinical, sensitive and complex discussions.
According to management, this acquisition represents a significant step forward in AMN’s commitment to making healthcare more accessible. Enhancing language support across more moments in the healthcare journey enables healthcare organizations to create seamless experiences for both patients and care teams, while still leveraging the critical expertise of qualified interpreters.
AMN Stock Trend Following the News
Following the announcement, shares of AMN lost 2.3% at yesterday’s closing. In the year-to-date period, the stock surged 92.4% against the industry’s 17.9% decline. The S&P 500 has risen 8.3% in the same timeframe.
The integration of AI-assisted translation capabilities enables AMN Healthcare to offer more comprehensive end-to-end language support while preserving the critical role of human interpreters. The transaction also reflects the increasing adoption of AI solutions in healthcare administration. By combining technology-driven efficiency with human expertise, AMN is well positioned to help healthcare organizations address the rising demand for accessible and equitable patient communication.
AMN currently has a market capitalization of $1.20 billion.
Image Source: Zacks Investment Research
More on the News
Jaide Health delivers AI-assisted language support for routine verbal interactions and document translations, including patient intake, discharge instructions and other everyday communications.These capabilities reduce delays and improve language accessibility in situations where healthcare staff and patients often face communication barriers outside direct physician or acute-care encounters.For complex medical conversations, professional human interpreters remain central to ensure accuracy, empathy and patient safety.
The Jaide Health platform is already being used by clients across multiple care settings, demonstrating its ability to improve communication workflows and patient interactions. As part of the transaction, Jaide Health’s team will become part of AMN Healthcare. The companies have not disclosed the financial details of the agreement.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the AI-enabled translation services market was valued at $6.51 billion in 2026 and is expected to witness a CAGR of 25.6% through 2035.
Factors like the increasing demand for real-time translators, rapid adoption by the healthcare sector and the advancements in LLMs and GenAI that offer precise and context-aware translation services with cost efficiency are boosting the market’s growth.
Other News
AMN Healthcare recently delivered a strong first-quarter 2026 performance, fueled by labor disruption activity, growth in nurse and allied staffing, improving international recruitment and expanding technology-driven workforce solutions. The company’s AI-powered tools and the WorkWise platform continued to gain traction, enhancing hiring efficiency. However, weakness in Physician and Leadership Solutions persisted due to softer demand and competitive pressures. Management expects AI adoption and operational efficiencies to support sustainable revenue and profitability growth.
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
AMN Expands Language Services Portfolio With Jaide Health Deal
Key Takeaways
AMN Healthcare Services (AMN - Free Report) recently announced the acquisition of Jaide Health, an AI-enabled medical interpretation and translation platform, to expand language access for patients with Limited English Proficiency across the healthcare journey. The move enhances AMN’s Language Services capabilities by extending language assistance to important touchpoints before and after treatment while maintaining the critical role of qualified human interpreters for clinical, sensitive and complex discussions.
According to management, this acquisition represents a significant step forward in AMN’s commitment to making healthcare more accessible. Enhancing language support across more moments in the healthcare journey enables healthcare organizations to create seamless experiences for both patients and care teams, while still leveraging the critical expertise of qualified interpreters.
AMN Stock Trend Following the News
Following the announcement, shares of AMN lost 2.3% at yesterday’s closing. In the year-to-date period, the stock surged 92.4% against the industry’s 17.9% decline. The S&P 500 has risen 8.3% in the same timeframe.
The integration of AI-assisted translation capabilities enables AMN Healthcare to offer more comprehensive end-to-end language support while preserving the critical role of human interpreters. The transaction also reflects the increasing adoption of AI solutions in healthcare administration. By combining technology-driven efficiency with human expertise, AMN is well positioned to help healthcare organizations address the rising demand for accessible and equitable patient communication.
AMN currently has a market capitalization of $1.20 billion.
Image Source: Zacks Investment Research
More on the News
Jaide Health delivers AI-assisted language support for routine verbal interactions and document translations, including patient intake, discharge instructions and other everyday communications.These capabilities reduce delays and improve language accessibility in situations where healthcare staff and patients often face communication barriers outside direct physician or acute-care encounters.For complex medical conversations, professional human interpreters remain central to ensure accuracy, empathy and patient safety.
The Jaide Health platform is already being used by clients across multiple care settings, demonstrating its ability to improve communication workflows and patient interactions. As part of the transaction, Jaide Health’s team will become part of AMN Healthcare. The companies have not disclosed the financial details of the agreement.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the AI-enabled translation services market was valued at $6.51 billion in 2026 and is expected to witness a CAGR of 25.6% through 2035.
Factors like the increasing demand for real-time translators, rapid adoption by the healthcare sector and the advancements in LLMs and GenAI that offer precise and context-aware translation services with cost efficiency are boosting the market’s growth.
Other News
AMN Healthcare recently delivered a strong first-quarter 2026 performance, fueled by labor disruption activity, growth in nurse and allied staffing, improving international recruitment and expanding technology-driven workforce solutions. The company’s AI-powered tools and the WorkWise platform continued to gain traction, enhancing hiring efficiency. However, weakness in Physician and Leadership Solutions persisted due to softer demand and competitive pressures. Management expects AI adoption and operational efficiencies to support sustainable revenue and profitability growth.
AMN Healthcare Services Inc Price
AMN Healthcare Services Inc price | AMN Healthcare Services Inc Quote
AMN’s Zacks Rank & Key Picks
AMN Healthcare currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.